Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Disfunções em glândulas salivares são frequentes no diabetes e na hipertensão arterial. Glândulas salivares foram removidas para analisar o conteúdo das proteinas SGLT1 e PKA em ratos Wistar Kyoto (WKY), WKY diabéticos (WKY-D), espontaneamente hipertensos (SHR) e SHR diabéticos (SHR-D). A atividade simpática para as glândulas salivares também foi avaliada. A atividade simpática foi aumentada em SHR (P<0,001) comparado com WKY; e diminuída após a induçao do diabetes em WKY and SHR (P<0,05). A regulação da subunidade catalítica da PKA e da proteína SGLT1 em membrana plasmática foram paralelas com a atividade simpática. Em ratos diabéticos e/ou hipertensos, a análise da imunohistoquímica mostrou aumento da proteína SGLT1 na membrana luminal de células ductais, onde isto pode promover captação de água, reduzindo o fluxo salivar. Confirmando isso, a secreção salivar não-estimulada foi reduzida (P<0,001) em WKY-D, SHR e SHR-D. Os resultados mostram que o aumento da SGLT1 luminal foi inversamente proporcional com o fluxo salivar em ratos diabéticos e hipertensos. Isto indica o papel do transporte de água da SGLT1 e, pelo aumento da reabsorção de água, pode explicar a hiposalivação em indivíduos diabéticos e hipertensos. / Salivary gland dysfunction is a feature in diabetes and hypertension. In Wistar Kyoto rats (WKY), diabetic WKY (WKY-D), spontaneously hypertensive rats (SHR) and diabetic SHR (SHR-D), salivary glands were harvested for SGLT1 and PKA protein expression analysis. Moreover, sympathetic nerve activity to the salivary glands was measured. Diabetes decreased the nerve activity in WKY and SHR (P<0.05), pointing out that it was higher in SHR, as compared to WKY (P<0.001). The regulation of catalytic subunit of PKA and plasma membrane SGLT1 protein were parallel to the sympathetic nerve activity. In diabetic and/or hypertensive rats, imunohistochemical analysis showed increased SGLT1 protein in luminal membrane of ductal cells, where it may promote water uptake, reducing the salivary flow. Confirming that, nonstimulated salivary secretion was reduced (P<0.001) in WKY-D, SHR and SHR-D rats. The results show in luminal membrane of ductal cells SGLT1 protein increased inversely proportional to the nonstimulated salivary flux in diabetic and hypertensive rats. This indicates the water transporter role of SGLT1 and, by increasing salivary water reabsorption, may explain the hyposalivation complained by diabetic subjects.

Disfunções em glândulas salivares são frequentes no diabetes e na hipertensão arterial. Glândulas salivares foram removidas para analisar o conteúdo das proteinas SGLT1 e PKA em ratos Wistar Kyoto (WKY), WKY diabéticos (WKY-D), espontaneamente hipertensos (SHR) e SHR diabéticos (SHR-D). A atividade simpática para as glândulas salivares também foi avaliada. A atividade simpática foi aumentada em SHR (P<0,001) comparado com WKY; e diminuída após a induçao do diabetes em WKY and SHR (P<0,05). A regulação da subunidade catalítica da PKA e da proteína SGLT1 em membrana plasmática foram paralelas com a atividade simpática. Em ratos diabéticos e/ou hipertensos, a análise da imunohistoquímica mostrou aumento da proteína SGLT1 na membrana luminal de células ductais, onde isto pode promover captação de água, reduzindo o fluxo salivar. Confirmando isso, a secreção salivar não-estimulada foi reduzida (P<0,001) em WKY-D, SHR e SHR-D. Os resultados mostram que o aumento da SGLT1 luminal foi inversamente proporcional com o fluxo salivar em ratos diabéticos e hipertensos. Isto indica o papel do transporte de água da SGLT1 e, pelo aumento da reabsorção de água, pode explicar a hiposalivação em indivíduos diabéticos e hipertensos. / Salivary gland dysfunction is a feature in diabetes and hypertension. In Wistar Kyoto rats (WKY), diabetic WKY (WKY-D), spontaneously hypertensive rats (SHR) and diabetic SHR (SHR-D), salivary glands were harvested for SGLT1 and PKA protein expression analysis. Moreover, sympathetic nerve activity to the salivary glands was measured. Diabetes decreased the nerve activity in WKY and SHR (P<0.05), pointing out that it was higher in SHR, as compared to WKY (P<0.001). The regulation of catalytic subunit of PKA and plasma membrane SGLT1 protein were parallel to the sympathetic nerve activity. In diabetic and/or hypertensive rats, imunohistochemical analysis showed increased SGLT1 protein in luminal membrane of ductal cells, where it may promote water uptake, reducing the salivary flow. Confirming that, nonstimulated salivary secretion was reduced (P<0.001) in WKY-D, SHR and SHR-D rats. The results show in luminal membrane of ductal cells SGLT1 protein increased inversely proportional to the nonstimulated salivary flux in diabetic and hypertensive rats. This indicates the water transporter role of SGLT1 and, by increasing salivary water reabsorption, may explain the hyposalivation complained by diabetic subjects.

The intestinal epithelium is able to adapt to varying blood flow and, thus, oxygen availability. Still, the adaptation fails under pathologic situations. A better understanding of the mechanisms underlying the epithelial adaptation to hypoxia could help to improve the therapeutic approach. We hypothesized that the short-term adaptation to hypoxia is mediated via AMP-activated protein kinase (AMPK) and that it is coupled to the long-term adaptation by a common regulation mechanism, the HIF-hydroxylase enzymes. Further, we hypothesized the transepithelial transport of glucose to be part of this short-term adaptation. We conducted Ussing chamber studies using isolated lagomorph jejunum epithelium and cell culture experiments with CaCo-2 cells. The epithelia and cells were incubated under 100% and 21% O2, respectively, with the panhydroxylase inhibitor dimethyloxalylglycine (DMOG) or under 1% O2. We showed an activation of AMPK under hypoxia and after incubation with DMOG by Western blot. This could be related to functional effects like an impairment of Na+-coupled glucose transport. Inhibitor studies revealed a recruitment of glucose transporter 1 under hypoxia, but not after incubation with DMOG. Summing up, we showed an influence of hydroxylase enzymes on AMPK activity and similarities between hypoxia and the effects of hydroxylase inhibition on functional changes.

Les glandes sous-maxillaires sécrètent au repos la majorité de la salive totale. Parmi ses principales substances la constituant, la salive contient également du glucose. Le but de ce travail de recherche est de tenter de comprendre le mécanisme de transport du glucose dans la salive. Des études immunohistochimiques ont été menées sur tissus sous-maxillaires humains. GLUT1, GLUT4 et SGLT1 ont été détectés au niveau des cellules ductales des glandes sous-maxillaires alors que les cellules acinaires semblent équipées principalement de GLUT1 et SGLT1. GLUT2, dans les cellules ductales humaines, semble présent de manière peu importante.Sur glandes sous-maxillaires de rats, les études d’immunohistochimie, de Western blot et de qRT-PCR ont révélé la présence de GLUT1, de GLUT4 et de SGLT1 au niveau des cellules ductales. Les cellules acinaires, quant à elles, révèlent la présence de GLUT1 et de SGLT1. Les études concernant la capture de glucose et le métabolisme de glucose sur glandes sous-maxillaires de rats ont indiqué que le glucose était transporté par les cellules ductales et les cellules acinaires. Cependant, les cellules ductales transportent plus rapidement le glucose et le métabolisent 2 à 3 fois plus que les cellules acinaires. Les cellules ductales, en présence d’agents inhibiteurs tels que la cytochalasine B ou la phloridzine, capturent moins de glucose par le biais de GLUT1 et SGLT1, respectivement. Dans les cellules acinaires, seule la cytochalasine B inhibe le transport du glucose. SGLT1 semble très peu fonctionnel au niveau des cellules acinaires. L’une des originalités de ce travail repose également sur la mise en évidence de la présence du transporteur GLUT4, insulino-dépendant, dans les cellules ductales de glandes sous-maxillaires. Sur anneaux ductaux, l’insuline a démontré sa capacité à stimuler la capture de glucose. Eu égard à leur localisation préférentiellement basolatérale, la présence de 3 transporteurs (GLUT1, GLUT4 et SGLT1) dans les cellules ductales et de 2 transporteurs (SGLT1 et GLUT1) dans les cellules acinaires devrait permettre à ces cellules de subvenir à leurs besoins métaboliques. Ceci est particulièrement important au niveau des cellules ductales où un remaniement majeur des flux ioniques nécessite un soutien métabolique conséquent, surtout en période prandiale. / Doctorat en Sciences dentaires / info:eu-repo/semantics/nonPublished

Le diabète de type 2 et l'obésité sont des problèmes de santé majeurs et les peuples autochtones sont particulièrement à risque. Pour remédier à ce problème largement répandu dans les populations autochtones canadiennes pour qui la médication moderne n’est pas culturellement adaptée, notre équipe s’est donné comme objectif d’étudier les activités potentielles antidiabétique et anti-obésité de la pharmacopée traditionnelle des Cris de la Baie James. Le but de cette étude est de tester l’hypothèse selon laquelle certaines plantes médicinales pourraient inhiber l'absorption intestinale du glucose, une activité anti-hyperglycémique qui, par la même occasion, contribuerait à combattre l’obésité. Les extraits éthanoliques de dix-sept plantes médicinales de la forêt boréale ont été testés dans des cellules intestinales Caco-2 et comparés à l’effet d’inhibiteurs compétitifs connus, tels que la phlorizine et la phlorétine. Ces inhibiteurs sont des composés polyphénoliques qui partagent de nombreuses caractéristiques structurelles avec des constituants moléculaires de plusieurs plantes Cri. Les résultats démontrent que treize des dix-sept extraits de plantes ont inhibé de façon significative l'absorption intestinale du 3H-D-glucose. Pour valider ces effets in vivo, quatre extraits ont été administrés à des rats Wistar par gavage intragastrique (250 mg/kg) en même temps qu’un bolus de glucose (3 g/kg). Suite à ce gavage, deux de ces extraits ont restreint l’augmentation de la glycémie d'environ 40% par rapport à un contrôle sans extrait. Ces résultats indiquent qu’une inhibition compétitive de l'absorption intestinale du glucose peut être atteinte par des extraits bruts de plantes médicinales. La prise de ces plantes durant les repas aiderait à un meilleur contrôle post-prandial de la glycémie, particulièrement chez les personnes à risque. / Type II diabetes and obesity are major health problems worldwide and aboriginal peoples are particularly at risk. To address this problem in Canadian native populations for whom modern pharmaceuticals are culturally misadapted, our team is testing the traditional pharmacopeia of the James Bay Cree for anti-diabetic and anti-obesity activities. More specifically, the aim of the present study was to define the effects of traditional plants on intestinal glucose absorption, an under-appreciated anti-hyperglycaemic and anti-obesity activity. Crude ethanol extracts of seventeen Boreal forest medicinal plants were examined in the Caco-2 human enterocytic cell line and compared to the competitive classical inhibitors phlorizin and phloretin. It is worth noting that the latter compounds are polyphenols that share many structural characteristics with components of several Cree plants. Thirteen of seventeen extracts were observed to significantly inhibit uptake when administered simultaneously with 3H-deoxyglucose. Inhibition was dose-dependent and, in a few cases, even surpassed that induced by a combination of the positive controls. To validate these effects in-vivo, four plant extracts were administered by intragastric gavage at 250 mg/kg to normal rats simultaneously with a 3 g/kg bolus of glucose. This resulted in a decrease in peak glycaemia by approximately 40% for two of them. These findings indicate that competitive inhibition of facilitative intestinal glucose uptake can be achieved by crude extracts of medicinal plants. Intake of the latter with meals may help control post-prandial glycaemia and reduce caloric intake in high risk populations.

Le diabète de type 2 et l'obésité sont des problèmes de santé majeurs et les peuples autochtones sont particulièrement à risque. Pour remédier à ce problème largement répandu dans les populations autochtones canadiennes pour qui la médication moderne n’est pas culturellement adaptée, notre équipe s’est donné comme objectif d’étudier les activités potentielles antidiabétique et anti-obésité de la pharmacopée traditionnelle des Cris de la Baie James. Le but de cette étude est de tester l’hypothèse selon laquelle certaines plantes médicinales pourraient inhiber l'absorption intestinale du glucose, une activité anti-hyperglycémique qui, par la même occasion, contribuerait à combattre l’obésité. Les extraits éthanoliques de dix-sept plantes médicinales de la forêt boréale ont été testés dans des cellules intestinales Caco-2 et comparés à l’effet d’inhibiteurs compétitifs connus, tels que la phlorizine et la phlorétine. Ces inhibiteurs sont des composés polyphénoliques qui partagent de nombreuses caractéristiques structurelles avec des constituants moléculaires de plusieurs plantes Cri. Les résultats démontrent que treize des dix-sept extraits de plantes ont inhibé de façon significative l'absorption intestinale du 3H-D-glucose. Pour valider ces effets in vivo, quatre extraits ont été administrés à des rats Wistar par gavage intragastrique (250 mg/kg) en même temps qu’un bolus de glucose (3 g/kg). Suite à ce gavage, deux de ces extraits ont restreint l’augmentation de la glycémie d'environ 40% par rapport à un contrôle sans extrait. Ces résultats indiquent qu’une inhibition compétitive de l'absorption intestinale du glucose peut être atteinte par des extraits bruts de plantes médicinales. La prise de ces plantes durant les repas aiderait à un meilleur contrôle post-prandial de la glycémie, particulièrement chez les personnes à risque. / Type II diabetes and obesity are major health problems worldwide and aboriginal peoples are particularly at risk. To address this problem in Canadian native populations for whom modern pharmaceuticals are culturally misadapted, our team is testing the traditional pharmacopeia of the James Bay Cree for anti-diabetic and anti-obesity activities. More specifically, the aim of the present study was to define the effects of traditional plants on intestinal glucose absorption, an under-appreciated anti-hyperglycaemic and anti-obesity activity. Crude ethanol extracts of seventeen Boreal forest medicinal plants were examined in the Caco-2 human enterocytic cell line and compared to the competitive classical inhibitors phlorizin and phloretin. It is worth noting that the latter compounds are polyphenols that share many structural characteristics with components of several Cree plants. Thirteen of seventeen extracts were observed to significantly inhibit uptake when administered simultaneously with 3H-deoxyglucose. Inhibition was dose-dependent and, in a few cases, even surpassed that induced by a combination of the positive controls. To validate these effects in-vivo, four plant extracts were administered by intragastric gavage at 250 mg/kg to normal rats simultaneously with a 3 g/kg bolus of glucose. This resulted in a decrease in peak glycaemia by approximately 40% for two of them. These findings indicate that competitive inhibition of facilitative intestinal glucose uptake can be achieved by crude extracts of medicinal plants. Intake of the latter with meals may help control post-prandial glycaemia and reduce caloric intake in high risk populations.